Business Context and Reporting Period
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing antibody therapeutics for solid tumors and hematological malignancies, including CTX-471, CTX-8371, CTX-8573 and an NKp30 innate cell engager platform. The unaudited Form 10-Q covers the three and nine months ended September 30, 2020.
The company completed a reverse merger on June 17, 2020, with Compass Therapeutics LLC treated as the accounting acquirer. On June 19, 2020, it completed a private placement of 12.1 million common shares at $5.00 per share, generating approximately $54.2 million of net proceeds.
Financial Highlights
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $3.7 million vs. $6.0 million | $10.5 million vs. $19.1 million |
| General and administrative expense | $5.3 million vs. $2.4 million | $9.4 million vs. $8.5 million |
| Total operating expenses | $9.0 million vs. $8.4 million | $19.9 million vs. $27.7 million |
| Net loss | $9.2 million vs. $8.6 million | $21.1 million vs. $28.1 million |
| Basic and diluted loss per share | $0.18 loss vs. $1.27 loss | $0.88 loss vs. $4.26 loss |
| Cash used in operating activities | Not separately reported | $20.2 million vs. $26.2 million |
Because the company has no product revenue, revenue-based margins are not meaningful. The accumulated deficit was $143.0 million at September 30, 2020.
Balance Sheet, Cash Flow and Liquidity
- Cash and cash equivalents were $55.5 million at September 30, 2020, compared with $25.3 million at December 31, 2019. Cash, cash equivalents and restricted cash totaled $55.8 million.
- Total assets were $60.7 million and stockholders’ equity was $47.3 million at September 30, 2020, compared with a $118.6 million stockholders’ deficit at December 31, 2019, primarily reflecting the reverse merger and equity financing.
- Nine-month financing cash flow was $50.4 million, consisting primarily of private-placement proceeds, net of issuance costs, partially offset by $3.8 million of debt principal repayments.
- Debt had a principal amount of $11.25 million at September 30, 2020, presented net on the balance sheet as $11.19 million. The debt bears interest at 6.25% at period-end, requires monthly principal payments of $625,000, and matures in March 2022.
- The credit facility requires a minimum cash balance of $6.0 million. The company reported compliance with its debt covenants at September 30, 2020.
- Management expects existing cash and cash equivalents to fund operating and capital requirements into the first quarter of 2022, but states that additional financing will be required thereafter and possibly sooner if assumptions change.
Material Changes Versus Prior Comparable Period
- Nine-month net loss improved by $7.0 million, primarily because research and development expense declined by $8.6 million following reduced staffing, completion of CTX-471 preclinical work and the absence of certain 2019 milestone payments.
- Third-quarter net loss increased by $0.6 million despite lower research and development expense, primarily because general and administrative expense increased by $2.9 million.
- General and administrative expense rose due to higher legal and professional fees, facility costs and $2.5 million of third-quarter stock-based compensation, including stock options issued in August 2020.
- The company paid a $1.1 million debt-related success fee upon closing the merger. The related derivative liability was reduced to zero; the nine-month results included a $0.6 million change in fair value expense.
- Common shares outstanding increased substantially following the merger and private placement. The company reported 51.0 million common shares outstanding at September 30, 2020 and 52.1 million shares outstanding as of November 2, 2020.
Guidance, Outlook, Risks and Unusual Items
- Management expects research and development spending to increase as CTX-471 advances through Phase 1 development, CTX-8371 progresses toward IND-enabling studies and the company advances CTX-8573 and the NKp30 program.
- The company expects general and administrative costs to increase as it expands operations and incurs public-company compliance costs.
- COVID-19 caused, and may continue to cause, reduced patient and site access, delayed clinical-site initiation, limited site personnel and disruptions to suppliers and clinical development timelines.
- The company has no approved products, has never generated product-sale revenue and expects significant operating losses for the foreseeable future. It may never achieve profitability.
- Clinical, regulatory, manufacturing and intellectual-property risks are significant. CTX-471 is in Phase 1, while CTX-8371, CTX-8573 and other programs remain earlier stage. The filing identifies treatment-related serious adverse events and immune-related dose-limiting toxicities in the CTX-471 trial as of May 24, 2020.
- Future financing may dilute existing stockholders or require restrictive debt terms, collaborations or licenses that could reduce the company’s rights to its technology and product candidates.
- The common stock was not listed on a national securities exchange or quoted on an over-the-counter market as of the filing. The filing states there was no established trading market and no assurance that one would develop.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2020; neither management nor the independent registered public accounting firm had performed a Section 404 internal-control evaluation for the periods presented.
Investor Verification Items
- Verify the company’s actual cash burn and available liquidity against the stated runway into the first quarter of 2022.
- Monitor required monthly debt amortization, the March 2022 maturity and compliance with the $6.0 million minimum cash covenant.
- Assess clinical progress, enrollment, safety data and COVID-19-related delays for CTX-471, and development milestones for CTX-8371 and CTX-8573.
- Reconcile post-merger share counts, registered resale shares, outstanding options and potential dilution from the 2020 equity incentive plan.
- Review future financing needs and the potential effect of equity dilution, debt restrictions or licensing and collaboration transactions.
- Confirm the status of any trading-market development, exchange listing plans and liquidity for the common stock.